Bladder Cancer - Results from #40

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/ 3 mRNA Expression January 9, 2023

Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. January 9, 2023

Pathological pelvic lymph node involvement in muscle-invasive bladder patients treated with radical cystectomy: A narrative review. January 9, 2023

Quality of Life and Symptom Burden in Bladder Cancer Patients Receiving Immunotherapy - Expert Commentary January 6, 2023

Prospective Evaluation of Health-Related Quality of Life in Patients with Metastatic Urothelial Carcinoma Undergoing Immunotherapy with Pembrolizumab: Symptom Burden Can Predict Survival January 6, 2023

CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. January 6, 2023

Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab. January 6, 2023

Treatment of BCG-Unresponsive NMIBC with IL-15 Superagonist - Expert Commentary January 5, 2023

Longitudinal associations of adherence to lifestyle recommendations and health-related quality of life in patients with non-muscle invasive bladder cancer. January 5, 2023

Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer. January 5, 2023

Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review. January 4, 2023

Implementing a Checklist for Transurethral Resection of Bladder Tumor to Standardize Outcome Reporting: When High-quality Resection Could Influence Oncological Outcomes. January 4, 2023

Clinical and treatment characteristics of secondary bladder malignancies following low dose rate brachytherapy for prostate cancer. January 3, 2023

The Japanese health care system-based cost-effectiveness of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer. January 3, 2023

Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer. January 2, 2023

Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. January 2, 2023

Could we safely omit a Repeat Transurethral Resection of the Bladder (re-TURB) after Hexaminolevulinate Photodynamic Diagnostics (PDD)-TURB? December 30, 2022

AB0 blood groups and oncological and functional outcomes in bladder cancer patients treated with radical cystectomy. December 30, 2022

Radical cystectomy and urinary diversion outcomes in patients with single vs. double renal unit: A 2:1 matched-pair analysis. December 29, 2022

Natural history of multiple recurrences in intermediate-risk non-muscle invasive bladder cancer: lessons from a prospective cohort. December 29, 2022

Page 3 of 453

email news signup